RxDoctor Payments Data

Bahar Bastani, MD

Nephrology · St Louis, MONPI 1326059957

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $53,290 of the $87,262 with a category attached, or 61.1%. 15 manufacturers reported payments, led by Travere Therapeutics, Inc. at 55.9% of the total. Reporting peaked in 2023 at $37,810 and has fallen 74.9% since, to $9,503 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,262in general payments, 2019–2025

Across 165 payments — averaging $528.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$49K
  • Amgen$22K
  • Alnylam Pharmaceuticals Inc.$11K
  • Calliditas Therapeutics US Inc.$5K
  • Mallinckrodt Hospital Products Inc.$549
  • Otsuka America Pharmaceutical, Inc.$234
  • plus $702 from 9 others

What the payments were for

  • Consulting fees$13,13015%
  • Speaking & faculty fees$53,29061%
  • Travel & lodging$14,99317%
  • Food & beverage$5,5856%
  • Education$2640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,262 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$43,296
Medicare patients
138
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Everolimus12$152,854
Thiola EcTiopronin12$91,577
LokelmaSodium Zirconium Cyclosilicate14$19,935
Cinacalcet Hcl51$17,168
JardianceEmpagliflozin24$15,495
EliquisApixaban24$13,666
FarxigaDapagliflozin Propanediol20$12,619
Envarsus XrTacrolimus27$11,022
Tacrolimus26$6,003
Icosapent Ethyl34$5,645
VascepaIcosapent Ethyl15$5,132
Calcitriol259$3,575
Cyclosporine ModifiedCyclosporine, Modified26$3,178
Potassium Citrate ErPotassium Citrate39$2,887
Mycophenolate Mofetil32$2,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$15,49524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.

Other nephrology in St Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →